Dystrophic epidermolysis bullosa

Epidermolysis bullosa is a group of genetic conditions that cause the skin to be very fragile and to blister easily. Blisters and skin erosions form in response to minor injury or friction, such as rubbing or scratching. Dystrophic epidermolysis bullosa (DEB) is one of the major forms of epidermolysis bullosa. The signs and symptoms of this condition vary widely among affected individuals. In mild cases, blistering may primarily affect the hands, feet, knees, and elbows. Severe cases of this condition involve widespread blistering that can lead to vision loss, disfigurement, and other serious medical problems.

Researchers classify dystrophic epidermolysis bullosa into three major types. Although the types differ in severity, their features overlap significantly and they are caused by mutations in the same gene.

Autosomal recessive dystrophic epidermolysis bullosa, Hallopeau-Siemens type (RDEB-HS) is the most severe, classic form of the condition. Affected infants are typically born with widespread blistering and areas of missing skin, often caused by trauma during birth. Most often, blisters are present over the whole body and affect mucous membranes such as the moist lining of the mouth and digestive tract. As the blisters heal, they result in severe scarring. Scarring in the mouth and esophagus can make it difficult to chew and swallow food, leading to chronic malnutrition and slow growth. Additional complications of progressive scarring can include fusion of the fingers and toes, loss of fingernails and toenails, joint deformities (contractures) that restrict movement, and eye inflammation leading to vision loss. Additionally, young adults with the classic form of dystrophic epidermolysis bullosa have a very high risk of developing a form of skin cancer called squamous cell carcinoma, which tends to be unusually aggressive and is often life-threatening.

A second type of autosomal recessive dystrophic epidermolysis bullosa is known as the non-Hallopeau-Siemens type (non-HS RDEB). This form of the condition is somewhat less severe than the classic type and includes a range of subtypes. Blistering is limited to the hands, feet, knees, and elbows in mild cases, but may be widespread in more severe cases. Affected people often have malformed fingernails and toenails. Non-HS RDEB involves scarring in the areas where blisters occur, but this form of the condition does not cause the severe scarring characteristic of the classic type.

The third major type of dystrophic epidermolysis bullosa is known as the autosomal dominant type (DDEB). The signs and symptoms of this condition tend to be milder than those of the autosomal recessive forms, with blistering often limited to the hands, feet, knees, and elbows. The blisters heal with scarring, but it is less severe. Most affected people have malformed fingernails and toenails, and the nails may be lost over time. In the mildest cases, abnormal nails are the only sign of the condition.
Frequency
Considered together, the incidence of all types of dystrophic epidermolysis bullosa is estimated to be 6.5 per million newborns in the United States. The severe autosomal recessive forms of this disorder affect fewer than 1 per million newborns.

Causes
Mutations in the *COL7A1* gene cause all three major forms of dystrophic epidermolysis bullosa. This gene provides instructions for making a protein that is used to assemble type VII collagen. Collagens are molecules that give structure and strength to connective tissues, such as skin, tendons, and ligaments, throughout the body. Type VII collagen plays an important role in strengthening and stabilizing the skin. It is the main component of structures called anchoring fibrils, which anchor the top layer of skin, called the epidermis, to an underlying layer called the dermis.

*COL7A1* mutations alter the structure or disrupt the production of type VII collagen, which impairs its ability to help connect the epidermis to the dermis. When type VII collagen is abnormal or missing, friction or other minor trauma can cause the two skin layers to separate. This separation leads to the formation of blisters, which can cause extensive scarring as they heal. Researchers are working to determine how abnormalities of type VII collagen also underlie the increased risk of skin cancer seen in the severe form of dystrophic epidermolysis bullosa.

Inheritance Pattern
The most severe types of dystrophic epidermolysis bullosa are inherited in an autosomal recessive pattern. Autosomal recessive inheritance means that both copies of the *COL7A1* gene in each cell have mutations. Most often, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but do not show signs and symptoms of the condition.

A milder form of dystrophic epidermolysis bullosa has an autosomal dominant pattern of inheritance. Autosomal dominant inheritance means that one copy of the altered gene in each cell is sufficient to cause the disorder. About 70 percent of all people with autosomal dominant dystrophic epidermolysis bullosa have inherited an altered *COL7A1* gene from an affected parent. The remaining 30 percent of affected people have the condition as a result of a new mutation in the *COL7A1* gene. These cases occur in people with no history of the disorder in their family.

Other Names for This Condition
- Epidermolysis Bullosa Dystrophica
- Epidermolysis Bullosa, Dystrophic
Diagnosis & Management

Genetic Testing Information

• What is genetic testing?
  /primer/testing/genetictesting

• Genetic Testing Registry: Dystrophic epidermolysis bullosa

• Genetic Testing Registry: Generalized dominant dystrophic epidermolysis bullosa

• Genetic Testing Registry: Recessive dystrophic epidermolysis bullosa

Research Studies from ClinicalTrials.gov

• ClinicalTrials.gov
  https://clinicaltrials.gov/ct2/results?cond=%22Epidermolysis+Bullosa+Dystrophica%22+OR+%22dystrophic+epidermolysis+bulla%22

Other Diagnosis and Management Resources

• GeneReview: Dystrophic Epidermolysis Bullosa
  https://www.ncbi.nlm.nih.gov/books/NBK1304

• MedlinePlus Encyclopedia: Epidermolysis bullosa
  https://medlineplus.gov/ency/article/001457.htm

• MedlinePlus Encyclopedia: Squamous Cell Skin Cancer
  https://medlineplus.gov/ency/article/000829.htm

Additional Information & Resources

Health Information from MedlinePlus

• Encyclopedia: Epidermolysis bullosa
  https://medlineplus.gov/ency/article/001457.htm

• Encyclopedia: Squamous Cell Skin Cancer
  https://medlineplus.gov/ency/article/000829.htm

• Health Topic: Skin Conditions
  https://medlineplus.gov/skinconditions.html

Genetic and Rare Diseases Information Center

• Dystrophic epidermolysis bullosa
  https://rarediseases.info.nih.gov/diseases/2150/dystrophic-epidermolysis-bullosa
**Additional NIH Resources**

- National Institute of Allergy and Infectious Diseases
  https://www.niams.nih.gov/health-topics/epidermolysis-bullosa

**Educational Resources**

- MalaCards: dominant dystrophic epidermolysis bullosa
  https://www.malacards.org/card/dominant_dystrophic_epidermolysis_bullosa

- MalaCards: recessive dystrophic epidermolysis bullosa
  https://www.malacards.org/card/recessive_dystrophic_epidermolysis_bullosa

- Orphanet: Dystrophic epidermolysis bullosa
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=303

**Patient Support and Advocacy Resources**

- DebRA UK
  https://www.debra.org.uk/

- Dystrophic Epidermolysis Bullosa Research Association of America (DebRA)
  http://www.debra.org/

- Epidermolysis Bullosa Center, Cincinnati Children's Hospital Medical Center
  https://www.cincinnatichildrens.org/service/e/epidermolysis-bullosa

- Epidermolysis Bullosa Medical Research Foundation
  https://ebmrf.org/

- National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/epidermolysis-bullosa/

- Resource list from the University of Kansas Medical Center
  http://www.kumc.edu/gec/support/epidermo.html

**Clinical Information from GeneReviews**

- Dystrophic Epidermolysis Bullosa
  https://www.ncbi.nlm.nih.gov/books/NBK1304

**Scientific Articles on PubMed**

- PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28Epidermolysis+Bullosa+Dystrophica%5BMAJR%5D%29+AND+%28%28dystrophic+epidermolysis+bollosa%5BMAJR%5D%29+OR+%28epidermolysis+bullosa+dystrophica%5BTIAB%5D%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D
Catalog of Genes and Diseases from OMIM

- EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL DOMINANT
  http://omim.org/entry/131750
- EPIDERMOLYSIS BULLOSA DYSTROPHICA, AUTOSOMAL RECESSIVE
  http://omim.org/entry/226600

Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14726937
- De Benedittis M, Petrucci M, Favia G, Serpico R. Oro-dental manifestations in Hallopeau-Siemens-
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14987265
- Dharma B, Moss C, McGrath JA, Mellerio JE, Ilchyshyn A. Dominant dystrophic epidermolysis 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11260188
- Dystrophic Epidermolysis Bullosa Research Association of America (DebRA) 
  http://www.debra.org/
- Fine JD, Eady RA, Bauer EA, Briggaman RA, Bruckner-Tuderman L, Christiano A, Heagerty A, 
  classification system for inherited epidermolysis bullosa: Report of the Second International 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10827412
- Mallipeddi R, Bleck O, Mellerio JE, Ashton GH, Eady RA, McGrath JA. Dilemmas in distinguishing 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/14616374
- Pfendner EG, Lucky AW. Dystrophic Epidermolysis Bullosa, 2006 Aug 21 [updated 2015 Feb 26]. 
  In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, 
  Mefford HC, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/20301481
- Uitto J, Richard G. Progress in epidermolysis bullosa: from eponyms to molecular genetic 
  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15708287

Reprinted from Genetics Home Reference: 

Reviewed: January 2008
Published: August 6, 2019